Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 322

1.

Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes.

Sukupolvi-Petty S, Austin SK, Purtha WE, Oliphant T, Nybakken GE, Schlesinger JJ, Roehrig JT, Gromowski GD, Barrett AD, Fremont DH, Diamond MS.

J Virol. 2007 Dec;81(23):12816-26. Epub 2007 Sep 19.

2.

Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection.

Sukupolvi-Petty S, Brien JD, Austin SK, Shrestha B, Swayne S, Kahle K, Doranz BJ, Johnson S, Pierson TC, Fremont DH, Diamond MS.

J Virol. 2013 Aug;87(16):8826-42. doi: 10.1128/JVI.01314-13. Epub 2013 Jun 19.

3.

The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein.

Smith SA, de Alwis AR, Kose N, Harris E, Ibarra KD, Kahle KM, Pfaff JM, Xiang X, Doranz BJ, de Silva AM, Austin SK, Sukupolvi-Petty S, Diamond MS, Crowe JE Jr.

MBio. 2013 Nov 19;4(6):e00873-13. doi: 10.1128/mBio.00873-13.

4.

Dengue virus envelope domain III immunization elicits predominantly cross-reactive, poorly neutralizing antibodies localized to the AB loop: implications for dengue vaccine design.

Li XQ, Qiu LW, Chen Y, Wen K, Cai JP, Chen J, Pan YX, Li J, Hu DM, Huang YF, Liu LD, Ding XX, Guo YH, Che XY.

J Gen Virol. 2013 Oct;94(Pt 10):2191-201. doi: 10.1099/vir.0.055178-0. Epub 2013 Jul 12.

PMID:
23851440
5.

Genotype-specific neutralization and protection by antibodies against dengue virus type 3.

Brien JD, Austin SK, Sukupolvi-Petty S, O'Brien KM, Johnson S, Fremont DH, Diamond MS.

J Virol. 2010 Oct;84(20):10630-43. doi: 10.1128/JVI.01190-10. Epub 2010 Aug 11.

6.

Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2.

Sukupolvi-Petty S, Austin SK, Engle M, Brien JD, Dowd KA, Williams KL, Johnson S, Rico-Hesse R, Harris E, Pierson TC, Fremont DH, Diamond MS.

J Virol. 2010 Sep;84(18):9227-39. doi: 10.1128/JVI.01087-10. Epub 2010 Jun 30.

7.

Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein.

Oliphant T, Nybakken GE, Engle M, Xu Q, Nelson CA, Sukupolvi-Petty S, Marri A, Lachmi BE, Olshevsky U, Fremont DH, Pierson TC, Diamond MS.

J Virol. 2006 Dec;80(24):12149-59. Epub 2006 Oct 11.

8.

High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection.

Tsai WY, Lai CY, Wu YC, Lin HE, Edwards C, Jumnainsong A, Kliks S, Halstead S, Mongkolsapaya J, Screaton GR, Wang WK.

J Virol. 2013 Dec;87(23):12562-75. doi: 10.1128/JVI.00871-13. Epub 2013 Sep 11.

9.

The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1.

Shrestha B, Brien JD, Sukupolvi-Petty S, Austin SK, Edeling MA, Kim T, O'Brien KM, Nelson CA, Johnson S, Fremont DH, Diamond MS.

PLoS Pathog. 2010 Apr 1;6(4):e1000823. doi: 10.1371/journal.ppat.1000823.

10.

Analysis of epitopes on dengue virus envelope protein recognized by monoclonal antibodies and polyclonal human sera by a high throughput assay.

Lin HE, Tsai WY, Liu IJ, Li PC, Liao MY, Tsai JJ, Wu YC, Lai CY, Lu CH, Huang JH, Chang GJ, Wu HC, Wang WK.

PLoS Negl Trop Dis. 2012 Jan;6(1):e1447. doi: 10.1371/journal.pntd.0001447. Epub 2012 Jan 3.

11.

Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus.

Gromowski GD, Barrett ND, Barrett AD.

J Virol. 2008 Sep;82(17):8828-37. doi: 10.1128/JVI.00606-08. Epub 2008 Jun 18.

12.

Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions.

de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, White LJ, Diamond MS, Baric RS, Crowe JE Jr, de Silva AM.

Proc Natl Acad Sci U S A. 2012 May 8;109(19):7439-44. doi: 10.1073/pnas.1200566109. Epub 2012 Apr 12.

13.

The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity.

Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, Sukupolvi-Petty S, Navarro-Sanchez E, Young PR, de Silva AM, Rey FA, Varani L, Whitehead SS, Diamond MS, Harris E, Lanzavecchia A, Sallusto F.

Cell Host Microbe. 2010 Sep 16;8(3):271-83. doi: 10.1016/j.chom.2010.08.007.

14.
16.

Generation of Monoclonal Antibodies against Dengue Virus Type 4 and Identification of Enhancing Epitopes on Envelope Protein.

Tang CT, Liao MY, Chiu CY, Shen WF, Chiu CY, Cheng PC, Chang GJ, Wu HC.

PLoS One. 2015 Aug 26;10(8):e0136328. doi: 10.1371/journal.pone.0136328. eCollection 2015.

18.

Identification of a novel infection-enhancing epitope on dengue prM using a dengue cross-reacting monoclonal antibody.

Luo YY, Feng JJ, Zhou JM, Yu ZZ, Fang DY, Yan HJ, Zeng GC, Jiang LF.

BMC Microbiol. 2013 Aug 29;13:194. doi: 10.1186/1471-2180-13-194.

19.

Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones.

Smith SA, de Alwis AR, Kose N, Jadi RS, de Silva AM, Crowe JE Jr.

J Virol. 2014 Nov;88(21):12233-41. doi: 10.1128/JVI.00247-14. Epub 2014 Aug 6.

20.

Development of a humanized antibody with high therapeutic potential against dengue virus type 2.

Li PC, Liao MY, Cheng PC, Liang JJ, Liu IJ, Chiu CY, Lin YL, Chang GJ, Wu HC.

PLoS Negl Trop Dis. 2012;6(5):e1636. doi: 10.1371/journal.pntd.0001636. Epub 2012 May 1.

Supplemental Content

Support Center